Indeed today's letter from Agresti, Lalezari, and

Indeed today's letter from Agresti, Lalezari, and Seethamraju is very interesting in its backhand FDA criticism on LL dosing.

I did not understand until the publication of today's letter that 82% day-14 mortality reduction declined to 24% at day 28.

Oh My God.

Did they just need two more doses of leronlimab?

Oh My God.

PRO140 Lalezari journal articles say intravenous is way more than twice the dose of subcutaneous.

So my back-of-the-napkin calculations say that one IV dose followed by three subQ doses is something close to 3.5x two subQ doses.

The thesis that the leronlimab dose has been too low may also be supported by the wildly variable patient experiences.

Why do some patients seem to respond fully and quickly to leronlimab?

Is it because the covid disease varies from patient to patient?

Or is it because the threshold for leronlimab efficacy varies from patient to patient?

When they start hitting these patients with that first 700mg intravenous dose we are going to find out very quickly.

That 700mg intravenous dose should have been done a long time ago.